Literature DB >> 15209153

13C-breath tests in the study of microsomal liver function.

E C Nista1, L Fini, A Armuzzi, M Candelli, M A Zocco, I A Cazzato, G Merra, R Finizio, L Miele, A Grieco, G Gasbarrini, A Gasbarrini.   

Abstract

Conventional liver tests can be used to estimate a mixture of injury and function but none of these may be regarded as a reliable marker either to quantify functional hepatic reserve or to reflect life-threatening complications of acute and chronic liver diseases. To overcome this limit, many dynamic tests have been developed in order to evaluate the "hepatic functional mass". Among these tests we can include breath tests with 13C-labeled substrates undergoing different metabolic pathways. As concerning the evaluation of microsomal function, two main categories of breath tests have been developed based on the limiting step in the different substrates metabolism. The first group include aminopyrine, caffeine and diazepam, all substrates with a metabolism independent from hepatic blood flow and dependent almost exclusively from the enzymatic activity of different cytochromes P450. The other group is composed of substrates with flow dependent metabolism like methacetin, phenacetin, erythromycin. The aim of this review is to describe the clinical applications of microsomal liver breath tests in different hepatic diseases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15209153

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  7 in total

Review 1.  Alternative Sampling Strategies for Cytochrome P450 Phenotyping.

Authors:  Pieter M M De Kesel; Willy E Lambert; Christophe P Stove
Journal:  Clin Pharmacokinet       Date:  2016-02       Impact factor: 6.447

Review 2.  Evolving therapies for liver fibrosis.

Authors:  Detlef Schuppan; Yong Ook Kim
Journal:  J Clin Invest       Date:  2013-05-01       Impact factor: 14.808

3.  Point-of-care continuous (13)C-methacetin breath test improves decision making in acute liver disease: results of a pilot clinical trial.

Authors:  Gadi Lalazar; Tomer Adar; Yaron Ilan
Journal:  World J Gastroenterol       Date:  2009-02-28       Impact factor: 5.742

Review 4.  (13)CO2 breath tests in non-invasive hepatological diagnosis.

Authors:  Joanna Musialik; Krzysztof Jonderko; Anna Kasicka-Jonderko; Magdalena Buschhaus
Journal:  Prz Gastroenterol       Date:  2015-01-14

Review 5.  13C Methacetin Breath Test for Assessment of Microsomal Liver Function: Methodology and Clinical Application.

Authors:  Katarzyna Gorowska-Kowolik; Agata Chobot; Jaroslaw Kwiecien
Journal:  Gastroenterol Res Pract       Date:  2017-07-05       Impact factor: 2.260

6.  A continuous 13C methacetin breath test for noninvasive assessment of intrahepatic inflammation and fibrosis in patients with chronic HCV infection and normal ALT.

Authors:  G Lalazar; O Pappo; T Hershcovici; T Hadjaj; M Shubi; H Ohana; N Hemed; Y Ilan
Journal:  J Viral Hepat       Date:  2008-07-11       Impact factor: 3.728

7.  Validation of a new prognostic model to predict short and medium-term survival in patients with liver cirrhosis.

Authors:  Tomasz Dziodzio; Robert Öllinger; Wenzel Schöning; Antonia Rothkäppel; Radoslav Nikolov; Andrzej Juraszek; Paul V Ritschl; Martin Stockmann; Johann Pratschke; Maximilian Jara
Journal:  BMC Gastroenterol       Date:  2020-08-12       Impact factor: 3.067

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.